
    
      The duration of the study for 1 patient will include a screening period of up to 21 days
      prior to first study drug administration, 3-week treatment cycle(s) (until 30 days after last
      SAR566658 administration), and a follow-up period. Each patient will be treated until
      radiological disease progression, unacceptable toxicity, or patient's refusal of further
      study treatment.
    
  